Creating advanced nanobodies for targeted cancer therapy
Official title: Development of Programmable Nanobodies for Multi-functionalized Biologics
Funded at Pearl Bio, INC. · NIH-10921861 · Data updated 2026-11-12
This study is working on creating tiny antibodies that can deliver cancer-fighting drugs right to tumors, making treatments more effective and with fewer side effects, so patients can have better options for fighting cancer.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pearl Bio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | June 1, 2024 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $295,259 |
| NIH project number | 1R43GM154591-01 |
| Project ID | NIH-10921861 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with specific types of cancer that could benefit from targeted therapies.
✕Less likely to help
Patients who do not have cancer or those whose cancer is not amenable to targeted therapy may not benefit from this research.
What this research studies
This research focuses on developing programmable nanobodies, which are small antibodies that can deliver cancer-fighting drugs directly to tumors. By improving the stability and effectiveness of these nanobodies, the project aims to enhance their ability to penetrate tissues and cells, thereby increasing the efficacy of cancer treatments. The approach involves designing these nanobodies to bind to specific cancer markers, allowing for more precise targeting and reduced side effects. Patients may benefit from more effective therapies with fewer adverse reactions.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments for patients.
How similar studies have gone: Previous research has shown promise in using nanobodies for targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
-
Pearl Bio, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Chattopadhyay, Souvik — Pearl Bio, INC.
- Study coordinator: Chattopadhyay, Souvik
Related research
Other NIH-funded projects on the same topics.
-
Creating advanced biologics for targeted cancer treatment
This study is working on creating new types of proteins that can be customized to better treat diseases like cancer and multiple sclerosis, making them safer and more effective for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.